Mobile phone text message reminders of antipsychotic medication: Is it time and who should receive them? A cross-sectional trust-wide survey of psychiatric inpatients

BMC Psychiatry

Volumn 14, Issue 1, 2014, Pages

  Bogart, Katherine ^a,b   Wong, Sook Kuan ^a   Lewis, Christine ^c   Akenzua, Anthony ^d   Hayes, Daniel ^a   Prountzos, Athanasios ^a   Okocha, Chike Ify ^d   Kravariti, Eugenia ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SPRINGFIELD UNIVERSITY HOSPITAL   (United Kingdom)

^c Erith Centre   (United Kingdom)

^d OXLEAS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antipsychotics; Electronic reminders; Inpatients; Medication adherence; Mobile phone; SMS

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; CROSS-SECTIONAL STUDY; FEMALE; HOSPITAL PATIENT; HUMAN; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PSYCHOLOGY; PSYCHOTIC DISORDERS; QUESTIONNAIRE; RECURRENT DISEASE; REMINDER SYSTEM; TEXT MESSAGING; UNITED KINGDOM;

ADULT; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; GREAT BRITAIN; HUMANS; INPATIENTS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PSYCHOTIC DISORDERS; RECURRENCE; REMINDER SYSTEMS; SURVEYS AND QUESTIONNAIRES; TEXT MESSAGING;

EID: 84892667987     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-14-15     Document Type: Article

References (46)

1. Rössler W, Salize HJ, van Os J, Riecher-Rössler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005, 15(4):399-409. 10.1016/j.euroneuro.2005.04.009, 15925493.
2. Harwood RH, Sayer AA, Hirschfeld M. Current and future worldwide prevalence of dependency, its relationship to total population, and dependency ratios. Bull World Health Organ 2004, 82(4):251-258. 2585969, 15259253.
3. World Health Organization Pharmacological treatment of mental disorders in primary health care http://whqlibdoc.who.int/publications/2009/9789241547697_eng.pdf, World Health Organization.
4. Mangalore R, Knapp M. Cost of Schizophrenia in England. J Ment Health Policy Econ 2007, 109(1):23-41.
5. Noel JM. ASHP therapeutic position statement on the use of second-generation antipsychotic medications in the treatment of adults with psychotic disorders. Am J Health Syst Pharm 2007, 64(8):863-876. 10.2146/ajhp060343, 17420192.
6. Möller-Leimkühler A. Burden of relatives and predictors of burden. Baseline results from the Munich 5-year-followup study on relatives of first hospitalized patients with schizophrenia or depression. Eur Arch Psychiatry Clin Neurosci 2005, 255(4):223-231. 10.1007/s00406-004-0550-x, 15549342.
7. World Health Organization Antipsychotic medications for psychotic disorders http://www.who.int/mental_health/mhgap/evidence/resource/psychosis_q1.pdf, World Health Organization.
8. Drapalski AL, Rosse RB, Peebles RR, Schwartz BL, Marvel CL, Deutsch SI. Topiramate improves deficit symptoms in a patient with Schizophrenia when added to a stable regimen of antipsychotic medication. Clin Neuropharmacol 2005, 24(5):290-294.
9. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353(12):1209-1223. 10.1056/NEJMoa051688, 16172203.
10. McCombs JS, Luo M, Johnstone BM, Shi L. The use of conventional antipsychotic medications for patients with schizophrenia in a medicaid population: therapeutic and cost outcomes over 2 years. Value Health 2000, 3(3):222-231. 10.1046/j.1524-4733.2000.33004.x, 16464186.
11. Docherty JP, Grogg AL, Kozma C, Lasser R. Antipsychotic partial compliance: impact on clinical outcomes in schizophrenia. Program and Abstracts of the 156th annual meeting of the American Psychiatric Association 2003, San Francisco, CA: American Psychiatric Association, May 17-22. Abstract NR172.
12. Nosé M, Barbui C, Tansella M. How often do patients with psychosis fail to adhere to treatment programmes? a systematic review. Psychol Med 2003, 33(7):1149-1160. 10.1017/S0033291703008328, 14580069.
13. World Health Organization Adherence to long-term therapies: evidence for action http://www.who.int/chp/knowledge/publications/adherence_report/en/, World Health Organization.
14. Masand PS, Roca M, Turner MS, Kane JM. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry 2009, 11(4):147-154. 10.4088/PCC.08r00612, 2736032, 19750066.
15. Llorca PM. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res 2008, 161(2):235-247. 10.1016/j.psychres.2007.07.012, 18849080.
16. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP. Assessment of adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiat Pract 2010, 16(1):34-45.
17. Nielsen RE, Lindström E, Nielsen J, Levander S. DAI-10 is as good as DAI-30 in schizophrenia. Eur Neuropsychopharmacol 2012, 22(10):747-750. 10.1016/j.euroneuro.2012.02.008, 22440974.
18. Baloush-Kleinman V, Levine SZ, Roe D, Shnitt D, Weizman A, Poyurovsky M. Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study. Schizoph Res 2011, 130(1-3):176-181.
19. Deegan PE. The importance of personal medicine: a qualitative study of resilience in people with psychiatric disabilities. Scand J Public Health Suppl 2005, 66:29-35.
20. Rettenbacher MA, Hofer A, Eder U, Hummer M, Kemmler G, Weiss EM, Fleischhacker WW, et al. Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes towards the illness and medication. J Clin Psychiatry 2004, 65(9):1211-1218. 10.4088/JCP.v65n0908, 15367047.
21. Roe D, Goldblatt H, Baloush-Klienman V, Swarbrick M, Davidson L. Why and how people decide to stop taking prescribed psychiatric medication: exploring the subjective process of choice. Psychiatr Rehabil J 2009, 33(1):38-46.
22. Horne R, Price D, Cleland J, Costa R, Covey D, Gruffydd-Jones K, Haughney J, Henrichsen SH, Kaplan A, Langhammer A, et al. Can asthma control be improved by understanding the patient's perspective?. BMC Pulm Med 2009, 7:8.
23. Clifford S, Barber N, Horne R. Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers. J Psychosom Res 2008, 64(1):41-46. 10.1016/j.jpsychores.2007.05.004, 18157998.
24. Vervloet M, Linn AJ, van Weert JC, De Bakker DH, Bouvy ML, van Dijk L. The effectiveness of interventions using electronic reminders to improve adherence to chronic medication: a systematic review of the literature. J Am Med Inform Assoc 2012, 19(5):696-704. 10.1136/amiajnl-2011-000748, 3422829, 22534082.
25. Pijnenborg GH, Withaar FK, Brouwer WH, Timmerman ME, van den Bosch RJ, Evans JJ. The efficacy of SMS text messages to compensate for the effects of cognitive impairments in schizophrenia. Br J Clin Psychol 2010, 49(Pt 2):259-274.
26. Granholm E, Ben-Zeev D, Link PC, Bradshaw KR, Holden JL. Mobile Assessment and Treatment for Schizophrenia (MATS): a pilot trial of an interactive text-messaging intervention for medication adherence, socialization, and auditory hallucinations. Schizophr Bull 2012, 38(3):414-425. 10.1093/schbul/sbr155, 3329971, 22080492.
27. Montes JM, Medina E, Gomez-Beneyto M, Maurino J. A short message service (SMS)-based strategy for enhancing adherence to antipsychotic medication in schizophrenia. Psychiatry Res 2012, 200(2-3):89-95.
28. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) 2000, Washington DC: USA, American Psychiatric Association.
29. Jeste DV, Palmer BW, Appelbaum PS, Golshan S, Glorioso D, Dunn LB, Kim K, Meeks T, Kraemer HC. A new brief instrument for assessing decisional capacity for clinical research. Arch Gen Psychiatry 2007, 64(8):966-974. 10.1001/archpsyc.64.8.966, 17679641.
30. Sahm L, MacCurtain A, Hayden J, Roche C, Richards HL. Electronic reminders to improve medication adherence-are they acceptable to patients?. Pharm World Sci 2009, 31(6):627-629. 10.1007/s11096-009-9327-7, 19731069.
31. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983, 13(1):177-183. 10.1017/S0033291700050182, 6133297.
32. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002, 63(10):892-909. 10.4088/JCP.v63n1007, 12416599.
33. McEvoy JP. The relationship between insight into psychosis and compliance with medications. Insight and Psychosis: Awareness of Illness in Schizophrenia and Related Disorders 2004, 311-333. New York: Oxford University Press, Amador X, David A, 2.
34. Mitchell AJ, Selmes T. Why don't patients take their medicine? Reasons and solutions in psychiatry. Advances Psych Treat 2007, 13:336-346.
35. Ofcom A nation addicted to smartphones http://consumers.ofcom.org.uk/2011/08/a-nation-addicted-to-smartphones/, Ofcom.
36. Office for National Statistics Percentage of Households with Selected Consumer Durables 2010, UK, http://www.ons.gov.uk/ons/rel/family-spending/family-spending/family-spending-2011-edition/index.html, Office for National Statistics.
37. Sanghara H, Kravariti E, Jakobsen H, Okocha C. Using short message services in mental health services: assessing feasibility. Mental Health Rev J 2010, 15(2):28-33.
38. Ben-Zeev D, Davis KE, Kaiser S, Krzsos I, Drake RE. Mobile technologies among people with serious mental illness: opportunities for future services. Adm Policy Ment Hlth 2013, 40(4):340-343.
39. Murali V, Oyebode F. Poverty, social inequality and mental health. Advances Psych Treat 2004, 10:216-224.
40. Alvarez-Jimenez M, Gleeson JF, Bendall S, Lederman R, Wadley G, Killackey E, McGorry PD. Internet-based interventions for psychosis: a sneak-peek into the future. Psychiat Clin N Am 2012, 35(3):735-747.
41. Sims H, Sanghara H, Hayes D, Wandiembe S, Finch M, Jakobsen H, Tsakanikos E, Okocha CI, Kravariti E. Text message reminders of appointments: a pilot intervention at four community mental health clinics in London. Psychiatr Serv 2012, 63(2):161-168.
42. Mutschler J, von Zitzewitz F, Rössler W, Grosshans M. Application of electronic diaries in patients with Schizophrenia and bipolar disorders. Psychiatr Danub 2012, 24(2):206-210.
43. Dolder CR, Lacro JP, Leckband S, Jeste DV. Interventions to improve antipsychotic medication adherence: review of recent literature. J Clin Psychopharmacol 2003, 23(4):389-399. 10.1097/01.jcp.0000085413.08426.41, 12920416.
44. Loga-Zec S, Loga S. Antipsychotics and the quality of life of schizophrenic patients. Psychiatr Danub 2010, 22(4):495-497.
45. Eack SM, Newhill CE. Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull 2007, 33(5):1225-1237. 10.1093/schbul/sbl071, 2632363, 17204532.
46. Velligan DI, Lam YW, Glahn DC, Barrett JA, Maples NJ, Ereshefsky L, Miller AL. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 2006, 32(4):724-742. 2632258, 16707778.